Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

Phase 2
3(50.0%)
N/A
3(50.0%)
6Total
Phase 2(3)
N/A(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT07090109Not ApplicableNot Yet Recruiting

PITCH - Impacting Hereditary Cancer Testing

Role: lead

NCT06677112Not ApplicableRecruiting

MCC-24-GYN-11: Comparison of Nodal Sampling in Endometrial Cancer

Role: lead

NCT03089554Phase 2Recruiting

Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies

Role: lead

NCT01519869Phase 2Completed

Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma

Role: lead

NCT03324945Not ApplicableCompleted

Chemotherapy-Induced Cognitive Impairment in Ovarian Cancer Patients

Role: lead

NCT02454036Phase 2Completed

Biobehavioral Intervention in Gynecologic Oncology Patients

Role: lead

All 6 trials loaded